1. Home
  2. ASAN vs BLLN Comparison

ASAN vs BLLN Comparison

Compare ASAN & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Asana Inc.

ASAN

Asana Inc.

HOLD

Current Price

$6.97

Market Cap

3.4B

Sector

Technology

ML Signal

HOLD

BLLN

BillionToOne Inc.

N/A

Current Price

$76.16

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASAN
BLLN
Founded
2008
2016
Country
United States
United States
Employees
N/A
713
Industry
Retail: Computer Software & Peripheral Equipment
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.9B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ASAN
BLLN
Price
$6.97
$76.16
Analyst Decision
Hold
Buy
Analyst Count
14
7
Target Price
$12.46
$126.71
AVG Volume (30 Days)
6.6M
372.4K
Earning Date
06-02-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
27.93
N/A
EPS
N/A
N/A
Revenue
$790,806,000.00
N/A
Revenue This Year
$10.19
$46.29
Revenue Next Year
$7.91
$30.14
P/E Ratio
N/A
N/A
Revenue Growth
9.25
N/A
52 Week Low
$5.38
$61.96
52 Week High
$19.00
$138.70

Technical Indicators

Market Signals
Indicator
ASAN
BLLN
Relative Strength Index (RSI) 60.71 45.20
Support Level $6.51 $64.99
Resistance Level $8.20 $83.20
Average True Range (ATR) 0.41 6.09
MACD 0.14 -1.22
Stochastic Oscillator 93.64 23.02

Price Performance

Historical Comparison
ASAN
BLLN

About ASAN Asana Inc.

Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: